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atent Foramen Ovale: Current
athology, Pathophysiology, and Clinical Status
idehiko Hara, MD,* Renu Virmani, MD,† Elena Ladich, MD,† Shannon Mackey-Bojack, MD,‡
ack Titus, MD,‡ Mark Reisman, MD,§ William Gray, MD,§ Masato Nakamura, MD,
ichael Mooney, MD,* Anil Poulose, MD,* Robert S. Schwartz, MD*
inneapolis and St. Paul, Minnesota; Gaithersburg, Maryland; Seattle, Washington; and Tokyo, Japan
Patent foramen ovale (PFO) is experiencing increased clinical interest as a congenital cardiac
lesion persisting into adulthood. It is implicated in several serious clinical syndromes,
including stroke, myocardial infarction, and systemic embolism. The PFO is now amenable
to percutaneous interventional therapies, and multiple novel technologies are either available
or under development for lesion closure. The PFO should be better understood to take
advantage of emerging percutaneous treatment options. This paper reviews PFO anatomy,
pathology, pathophysiology, and clinical impact and discusses current therapeutic
options. (J Am Coll Cardiol 2005;46:1768–76) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.038Cardiology Foundation
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Tatent foramen ovale (PFO) is experiencing much clinical
nterest as a congenital cardiac lesion that persists into
dulthood (1,2). It is a risk factor for several serious clinical
yndromes, including paradoxic systemic embolism, such as
schemic stroke (3), myocardial infarction (4), decompres-
ion sickness (DCS) in divers (5–7), and complications of
ulmonary embolism (8). Recent evidence further impli-
ates PFO as a possible cause of migraine headache through
echanisms not yet understood. The PFO is now amenable
o interventional percutaneous therapy (9), and multiple
ovel technologies are either available or under development
or lesion closure. The PFO pathology, pathophysiology,
nd clinical impact should be better understood as multiple
pproaches to percutaneous closure become available for
linical application. This paper reviews current knowledge
f this interesting lesion and summarizes future therapeutic
irections.
FO EMBRYOLOGY
he foramen ovale is necessary for blood flow across the
etal atrial septum. Beginning at four weeks of pregnancy
he primordial single atrium divides into right and left sides
y formation and fusion of two septa: the septum primum
nd septum secundum (Fig. 1) (10). The septum primum is
t first crescent-shaped, creating a large window connecting
he left and right atrium. It grows from the primordial atrial
oof toward the endocardial cushions, partially dividing the
ommon atrium into right and left halves. The endocardial
From the *Minneapolis Heart Institute and Foundation, Minneapolis, Minnesota;
CV Path, International Registry of Pathology, Gaithersburg, Maryland; ‡Jesse E.
dwards Registry of Cardiovascular Disease, St. Paul, Minnesota; §Swedish Medical
enter, Seattle, Washington; and the Division of Cardiovascular Medicine, Toho
niversity Ohashi Hospital, Tokyo, Japan.r
Manuscript received May 15, 2005; revised manuscript received June 16, 2005,
ccepted August 1, 2005.ushions are formed on the dorsal and ventral walls of the
trioventricular canal, approach each other, and fuse, divid-
ng the atrioventricular canal into right and left sides. The
oramen primum results, allowing oxygenated blood flow
rom the right to the left atrium. As the septum primum
rows toward the endocardial cushions, perforations de-
elop. These perforations form a large central window,
hrough programmed cell death, before the septum primum
nd endocardial cushions fuse.
The window made as these perforations fuse is the
oramen secundum, which also supplies shunt blood flow
rom the right to the left atrium. On the right side of the
eptum primum, another crescent-shaped membrane grows
rom the ventrocranial atrial wall: the septum secundum. It
radually grows and overlaps part of the foramen secundum,
orming an incomplete septal partition as an oval-shaped
indow. It is this window that becomes the foramen ovale.
he remaining septum primum forms a flap-like valve over
he foramen ovale, which typically closes by fusing with the
rowing septum secundum after birth.
As oxygenated blood flow in utero from the inferior vena
ava enters the right atrium, it crosses the patent foramen
vale and becomes the systemic circulation. Most blood
ow from the superior vena cava is routed through the
ricuspid valve and enters the right ventricle. At birth, right
eart pressure and pulmonary vascular resistance drop as
ulmonary arterioles open in reaction to oxygen filling the
lveolus. Left atrial pressure may also rise as the amount of
lood returning from the lungs increases. Either or both of
hese mechanisms may cause flap closure against the septum
ecundum. This fusion is complete by age two in about 75%
f individuals, but patency occurs in the other 25%. It is a
esidual, oblique, slit-shaped defect resembling a tunnel.
he reasons PFOs fail to close are unknown, but they likelyelate to multifactorial inheritance (11).
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he autopsy-derived prevalence of probe-patent PFO is
bout 27%, with decreasing prevalence at each decade of life
Table 1) (12). Patent foramen ovale slit width in the adult
anges from 1 to 19 mm (mean 4.9 mm), derived from
ostmortem formalin-fixed specimens. Figure 2 shows the
ross anatomy of the PFO. The PFO size increases with
ach decade of life. The mean diameter in the first decade is
.4 mm and in the tenth decade is 5.8 mm, perhaps
eflecting size-based selection over time where larger PFOs
Abbreviations and Acronyms
ASA  atrial septal aneurysm
ASD  atrial septal defect
DCS  decompression sickness
INR  international normalized ratio
MRI  magnetic resonance imaging
PFO  patent foramen ovale
TCD transcranial Doppler
TEE  transesophageal echocardiography
TIA  transient ischemic attack
TTE  transthoracic echocardiographyigure 1. Diagrammatic representation of patent foramen ovale developmen
onstantinides et al. (8). LA  left atrium; RA  right atrium.emain patent and smaller defects close. Greater PFO size
ncreases the risk of paradoxic embolism (13,14). Hetero-
eneity of size and morphology are pertinent to interven-
ional device closure selection (15).
FO ASSOCIATIONS: ATRIAL SEPTAL ANEURYSM
ND CHIARI NETWORKS
trial septal aneurysm. The PFO is associated with sev-
ral anatomic anomalies. A common association is atrial
eptal aneurysm (ASA), where part or all of the atrial
eptum shows aneurysmal dilatation (16), protruding into
ither atria (17). The ASA is defined as phasic septal
xcursion of at least 15 mm during the cardiorespiratory
ycle (18). The prevalence of ASA is 1% in autopsy-based
tudies (19), a number differing from echocardiographic
tudies. One transthoracic echo study found an ASA in
.22% of patients (18), and another reported a 1.9%
able 1. Patent Foramen Ovale Incidence Versus Age (12)
1–29 yrs 30%
0–79 yrs 25%
80 yrs 20%t from embryology. Right sagittal and coronal views. Adapted from
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Patent Foramen Ovale Review November 1, 2005:1768–76revalence using a definition of more than 10 mm excursion
16). M-mode transesophageal echocardiography (TEE) or
ntracardiac echocardiography is essential for precisely mea-
uring septal excursion in ASA.
The prevalence of ASA is higher when examined by
EE. One biplane TEE study reported ASA prevalence as
.2% and another reported 4% (20,21). In echocardio-
raphic studies of stroke patients, the prevalence is substan-
ially increased. Atrial septal aneurysm was found in 7.9% of
troke patients by biplane TEE (20) and 15% by single-
lane TEE (21).
Patent foramen ovale was detected by TEE using contrast
r Doppler color in 70% of ASA patients (17), suggesting
hat PFO detection is possible by intracardiac echocardiog-
aphy. Intracardiac echocardiography may be more comfort-
ble for the patient, and the Valsalva maneuver easier during
his procedure. However, it is more invasive (with potential
omplications) and more costly, and systematic evidence-
ased recommendations have not yet been established (22).
oreover, TEE may have better resolution.
A study in adults showed that 33% of patients with
SA also had PFO, although 32% had isolated ASA
23). Thus, ASA is more frequent in subjects with PFO,
nd ASA predicts PFO. The odds of PFO are 4.6 times
reater with ASA than without ASA (20). Atrial septal
neurysm is more frequent in stroke patients, but it is also
ore common in patients with PFO, making cause or
ffect uncertain.
hiari networks. The Chiari network is a remnant of the
ight valve of the sinus venosus, and its role is poorly
nderstood (24). It originates from a region of the eusta-
hian and thebesian valves with attachment to the upper
igure 2. Gross anatomy of the patent foramen ovale. (a) View from the r
he limbus (arrow) is seen forming a rounded cuff around the valve of the
ricuspid valve (S  septal leaflet; A  anterior leaflet) can be appreciated
he anterior leaflet of the mitral valve is seen below the probe.all of the right atrium or atrial septum. The eustachian malve is common but should be distinguished from Chiari
etworks because it does not attach to the upper wall of the
ight atrium or atrial septum, although it may be mobile and
enestrated. The prevalence of the Chiari network is 2% to
% in one autopsy study (25). A recent study using TEE
ith contrast suggested the clinical importance of Chiari
etworks (26). In 1,436 consecutive adult patients, 29 had
onfirmed Chiari networks (prevalence, 2%). This study
ound a frequent association between Chiari networks and
FO, with 83% of patients affected by both. Large right-
o-left shunting was found significantly more often in
atients with Chiari networks than in controls (55% vs.
2%, p  0.001). This study also found Chiari networks
ssociated with ASA in 24% of patients. The Chiari
etwork is more common in cryptogenic stroke patients
han in patients evaluated for other indications (4.6% vs.
.5%), and it may facilitate paradoxic embolism.
FO MICROANATOMY
ittle has been published about PFO histopathology, a
oint of increasing importance as percutaneous closure
echnologies are being developed that must interact with
hese tissues at cellular levels. Figures 3 to 5 show
icroanatomy of both patent (Figs. 3 and 4) and closed
oramen ovale (Fig. 5). The muscular atrial wall consists
f endocardium having endothelium and thick subendo-
helial layers of connective tissue rich in collagen and
lastin. A thicker myocardium lies beneath these struc-
ures, with loosely arranged musculature. The epicardium
overs the heart and is lined externally by a single layer of
trium showing a patent foramen ovale. Patency is determined by probing.
en ovale. The anatomic locations relative to the coronary sinus (CS) and
ame case viewed from the left atrium with probe demonstrating patency.ight a
foramesothelium.
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atent foramen ovale may be detected by transthoracic
chocardiography (TTE), TEE (27,28), transcranial Dopp-
er (TCD) (29), and sometimes by transmitral Doppler (30).
hese techniques were compared in studies of proven
mbolic stroke. One study revealed that TEE detected PFO
ost sensitively, showing a prevalence of 39%. In this study,
TE found PFOs in 18% and TCD found 27% (31). All
FOs detected by TTE and TCD were also detected by
EE. Six PFOs that could not be detected by TCD were
2 mm in size by TEE, implying that TCD may miss small
efects. Patent foramen ovale detection can be augmented
y cough or releasing a sustained Valsalva maneuver. It
pens the foramen when the right atrium fills with blood
rom the abdomen, while the left atrium is volume depleted
rior to blood passing through the pulmonary circulation
9). One TTE study showed that right-to-left shunting
hrough PFO increased when subjects performed the Val-
alva maneuver compared to rest (18% vs. 5%) (32). This
aneuver is now considered necessary to find right-to-left
hunts when performing echocardiography of any type, with
igure 3. Histopathology of the tissue membranes constituting a patent f
oramen ovale (box) with valve (arrow). The superior epicardial surface (E
redominantly of myocardium and adipose tissue. RA  right atrium. (b
hickened fibrotic right endocardial surface (arrow). The atrial septum (
nferiorly. Movat 1.25. (c) A higher magnification of the valve from the
yocardium is composed of bundles of cardiac myocytes. Movat 20. (d)
he endocardial surface (arrow), which consists of a thick layer of collagenr without contrast injection. The physical hole in the atrial wall may not be imaged, but detecting its shunt clearly
mproves sensitivity and specificity.
Transcranial Doppler is comparable to contrast TEE for
etecting PFO-related right-to-left shunts (type A, class II
vidence) (33), and is easy to perform at the bedside. One
tudy compared the sensitivity of transcranial color-coded
onography with TEE for detecting cardiac right-to-left
hunts. It found that transcranial color-coded sonography is
sensitive noninvasive method for detecting right-to-left
ardiac shunts, as sensitive as contrast TEE (34). Transcra-
ial Doppler has recently been augmented by power
-mode, a new technology allowing power display with
oppler velocity and frequency signals over selectable depth
anges along the transducer beam (35). Transcranial Dopp-
er M-mode enhances sensitivity to contrast bubble emboli
ver single-gated TCD examination (36).
FO: ASSOCIATED CLINICAL SYNDROMES
ryptogenic stroke. Approximately 40% of ischemic
trokes have no clear etiology and are therefore termed
ryptogenic. One study of 60 adults under 55 years of age
en ovale. (a) Longitudinal section of the atrial septum, showing a patent
a portion of the mitral valve (MV) are also seen. The septal wall consists
igher magnification of boxed area in panel a, showing the valve with a
this region consists of myocardium and becomes predominantly fibrotic
ide, showing a relatively thin endocardial surface (arrow). The underlying
her magnification of the valve from the opposite side (right), highlighting
elastic fibers. Movat 20.oram
) and
) A h
*) in
left sith ischemic stroke compared contrast echocardiographic
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Patent Foramen Ovale Review November 1, 2005:1768–76xaminations with 100 normal subjects. Patent foramen
vale prevalence was significantly higher in the stroke group
40%) than in controls (10%) (p  0.001). Patent foramen
vale was found in 26 stroke patients (54%) with no other
dentifiable cause, and the study concluded that PFO-
nduced paradoxic embolism is a cause of stroke (37). The
FO-ASA Study supports these findings, where 46% of
oung cryptogenic stroke patients had PFO (38). Cramer et
l. (39) evaluated young stroke patients (18 to 60 years old)
arly after stroke using magnetic resonance imaging (MRI)
enography. Pelvic deep venous thrombosis was increased in
he cryptogenic stroke population compared to controls
20% vs. 4%). The cryptogenic stroke group was signifi-
antly younger (42 vs. 49 years) with fewer risk factors for
therosclerosis, such as hypertension (73% vs. 26%) and
moking (17% vs. 7%). Patent foramen ovale prevalence was
ignificantly higher in the cryptogenic stroke group than in
ontrols (59% vs. 19%).
A prospective study of 598 patients (ages 18 to 55
ears) presenting with cryptogenic stroke showed that
6% had PFO, 1.7% had ASA, and 8.5% had both
bnormalities. Patients with both PFO and ASA who
igure 4. (a) Posterior longitudinal section of the atrial septum from the
vale are indicated. A portion of mitral valve (MV) is seen at the inferior m
alve of the foramen ovale. Note the thick endocardial layer of the limbus
1.25. (c) A higher magnification of the boxed portion of the limbus in pa
bers. Connective tissue bands are seen separating myocyte bundles. Movave had a stroke, are thus at higher risk for recurrent atroke, and preventive strategies other than aspirin should
e considered (40).
he platypnea-orthodeoxia syndrome. The platypnea-
rthodeoxia syndrome comprises both dyspnea (platypnea)
nd arterial desaturation in the upright position with im-
rovement in the supine position (orthodeoxia). It is un-
ommon, but several dozen cases are reported (41). Two
omponents must coexist to create this syndrome (42). One
s an anatomic defect and the other functional. The ana-
omic component must have an interatrial shunt, such as an
trial septal defect (ASD), PFO, fenestrated ASA, or
ntrapulmonary shunting.
A functional component induces the deformity in the
trial level and may occur while rising to an upright from a
ecumbent position. Cardiac causes also exist, including
ericardial effusion, constrictive pericarditis, and toxicity
rom drugs such as amiodarone (43). Key to this syndrome
s right atrial pressure elevation causing right-to-left shunt.
nterestingly, blood may flow from right to left at the atrial
evel even when right heart pressure is normal (44), as
ypically occurs with persistent eustachian valves. The de-
nitive treatment for platypnea-orthodeoxia is closure of the
case shown in Figure 3. The limbus (*) and valve (arrow) of the foramen
n. (b) Boxed area demonstrates the area where the limbus attaches to the
nderlying myocardium separated by wide connective tissue bands. Movat
characterized by a thickened endocardial surface rich in collagen and elastic
.same
argi
and utrial shunt (45).
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November 1, 2005:1768–76 Patent Foramen Ovale Reviewmbolism from DCS. Arterial gas embolism through an
SD was reported first in a scuba diver in 1986 (5). Type 1
CS is composed of localized joint pain, musculoskeletal
ain, and/or skin rash, and type 2 DCS consists of neuro-
ogic symptoms (limb tingling, paresthesias, severe head-
che with mental confusion, paraplegia, loss of conscious-
ess, audiovestibular symptoms, and dyspnea with chest
ain). The PFO at rest is significantly associated with type
DCS.
A recent study found a strong relationship between
FO size and DCS in a study of 230 divers (6). Another
tudy demonstrated the functional and anatomic charac-
eristics of PFO with and without DCS (7). This study
uggested that DCS was associated with right-to-left
hunting at rest. Atrial septal mobility and PFO diameter
re also associated with the risk of developing DCS.
igraine and vascular headache. Migraine and vascular
eadache may be related to PFO, according to an
nteresting new series of studies (46). Migraine headache
s a benign recurring syndrome of headache, nausea,
omiting, and/or other symptoms of neurologic dysfunc-
igure 5. Longitudinal section of the foramen ovale and atrial septum from
heart with closed foramen ovale. The left endocardial surface of the valve
s shown by the arrow. Note the slightly thickened left endocardial surface
arrow) compared to the right side. RA  right atrium.ion. Over 2,500,000 patients in the U.S. have at least cne migraine headache weekly, with a lifetime prevalence
f 18%. Migraine is a risk factor for cryptogenic stroke,
specially in young patients without atherosclerotic risk
actors. Vascular headache is generally attributed to a
ranial or cervical vascular disorder and is classed as
econdary. If paradoxic embolism causes headache, PFO
ay indeed be related.
One study demonstrated a significant relationship be-
ween PFO closure and improvement of migraine (with
ura) using TCD. In that study, 5 of 17 patients no longer
omplained of migraine, 10 of 17 were much improved, and
had no change 6 months after PFO closure (47). A further
tudy examined the relationship between PFO and migraine
ith or without aura (46). Patent foramen ovale prevalence
as 48% in migraine patients, 23% in those without
igraine, and 20% in controls. The difference between
atients with and without migraine and PFO was signifi-
ant, as was the difference in those with aura and the control
roup. However, the group without aura did not differ from
he control group in PFO prevalence. A recent study
emonstrated transcatheter closure of PFO caused complete
esolution or marked reduction in migraine frequency (48).
n this study, 162 consecutive patients with paradoxic
erebral embolism undergoing transcatheter PFO closure
ere investigated. Complete migraine resolution occurred
n 56% of patients, and 14% of patients reported a signifi-
ant (50%) reduction in migraine frequency. Patients
eported an 80% reduction in the mean number of migraine
pisodes per month after PFO closure (6.8  9.6 before
losure vs. 1.4  3.4 after closure, p  0.001). Another
ecent report similarly concluded that transcatheter closure
f PFO or ASD in patients with migraine headaches led to
igraine resolution or significant improvement in the ma-
ority (76%) of 89 adult patients (49).
The relationship between headache and right-to-left
hunt remains poorly characterized. Larger studies of PFO
nd headache are underway, as are randomized trials of
FO closure and migraine headache relief.
FO TREATMENT
edical therapy: recurrent stroke and paradoxic embo-
ism. It is uncertain whether anticoagulants such as warfa-
in and antiplatelet agents are effective as primary or
econdary therapy in preventing stroke among patients with
atent foramen ovale (50). The Lausanne Stroke Registry
ompared aspirin to oral anticoagulation in patients with
FO and cryptogenic stroke (51). This study investigated
2 patients treated with aspirin (250 mg/day) and 37
atients treated with oral anticoagulation (target interna-
ional normalized ratio [INR]  3.5). Eight patients
hanged regimens from oral anticoagulation to antiplatelet
gents after three months. The annual cerebrovascular event
ecurrence was 1.9% for cerebrovascular attack and 3.8% for
ombined transient ischemic attack (TIA) and attack during
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Patent Foramen Ovale Review November 1, 2005:1768–76hree years of follow-up. No significant difference was found
etween aspirin- and warfarin-treated patient groups.
Another prospective study examined PFO treated with
spirin (300 mg/day) for secondary prevention of stroke or
IA among young patients after a single first event. At four
ears, aspirin therapy did not improve the frequency of
ecurrent cerebrovascular events for high-risk patients, such
s those with septal abnormalities. Stroke recurrence was
.3% in patients with PFO, 0% in patients with atrial septal
neurysm, and 15.2% in those with both aneurysms and
FO (40).
The PFO in Cryptogenic Stroke Study Investigators
ound no difference in primary end points (recurrent stroke
nd death) between aspirin and warfarin treatment in PFO
atients at two years. This study concluded that larger PFO
r atrial septal aneurysms in stroke patients did not increase
he chance of adverse events (52).
The Warfarin-Aspirin Recurrent Stroke Study was a
rospective trial of 2,206 patients with prior stroke (53).
atients were randomized to aspirin (325 mg/day) or
arfarin (target INR 1.4 to 2.8). After two years, there were
o significant differences between aspirin and warfarin
reatment for recurrent stroke or death. Patients with
ryptogenic stroke showed no significant benefit in either
reatment group.
ercutaneous transcatheter closure. Many studies report
hat transcatheter PFO closure is safe and effective, with
fficacy ranging from 86% to 100% (54,55). Recurrent
eurologic and peripheral embolic events are reported as 0%
o 3.8% per year, possibly reflecting incomplete closure (56)
r thrombus formation around the device.
Krumsdorf et al. (57) reported 1,000 consecutive patients
ndergoing ASD and PFO closure using transcatheter
evices. Nine different technologies were used (Table 2).
he study reported thrombus formation in the left atrium (n
11), right atrium (n  6), or both (n  3) in 1.2% of
Table 2. Percutaneous PFO Closure Devices
Device Name De
Rashkind PDA Umbrella Double umbrell
Buttoned Device Square occluder
ASDOS Two self-openin
Angel Wings Two interconne
CadioSEAL Non-centering d
StarFLEX Self-centering d
Amplatzer Self-centering d
Helex Nitinol wire and
PFO-Star Two Ivalon squSD patients and in 2.5% of PFO patients (p  NS). Thrombus was diagnosed in 14 of 20 patients at four weeks
nd in 6 of 20 patients later than four weeks. The most
requent thrombus formation occurred on the CardioSEAL
evice (NMT Medical, Boston, Massachusetts) (7.1%). The
tarFLEX device (NMT Medical) had a 5.7% incidence of
hrombus formation, the PFO-Star device (Applied Bio-
etrics Inc., Burnville, Minnesota) 6.6%, the ASDOS
evice (Osypka Corp., Grenzach-Wyhlen, Germany) 3.6%,
he Helex device (WL Gore, Flagstaff, Arizona) 0.8%, and
he Amplatzer device (AGA Medical, Golden Valley, Min-
esota) had no thrombus formation. Several limitations
xist to this retrospective review, including the observation
hat heparin was typically reversed using protamine imme-
iately after the procedure. Also, hematologic screening was
ot performed before device implant, and often coagulopa-
hies are discovered only after thrombus is detected. Con-
lusions were that thrombus formation on closure devices is
ow and usually resolves with anticoagulation therapy.
Anzai et al. (58) described 66 patients with transcatheter
losure and found no thrombus on the Amplatzer device,
ut 22% of patients had thrombus on the CardioSEAL
evice. This report indicated that most thrombus disap-
eared or markedly diminished with additional anticoagu-
ation therapy. One patient underwent surgical device ex-
lantation owing to progressively increasing thrombus size
nd mobility despite intensive anticoagulation therapy.
URGICAL PFO CLOSURE
n the age of excellent percutaneous PFO closure methods
nd results, surgical closure has become rare. Several inves-
igators reported surgical PFO closure and cerebrovascular
vent results. Homma et al. (59) described the safety of
urgical PFO treatment, but could not prove superiority of
urgical approaches to prevent ischemic event recurrence. In
heir study, 28 patients with cryptogenic stroke underwent
Manufacturer
Bard
Billerica, MA
n Custom Medical Devices
Amarillo, TX
brellas Osypka Corp.
Grenzach-Wyhlen, Germany
quares Microvena Inc.
Vadnais, MN
umbrellas NMT Medical
Boston, MA
umbrellas NMT Medical
Boston, MA
discs AGA Medical
Golden Valley, MN
E covering WL Gore
Flagstaff, AZ
scs Applied Biometrics Inc.
Burnsville, MNsign
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November 1, 2005:1768–76 Patent Foramen Ovale Reviewlosure by open thoracotomy because they refused, could
ot take, or failed warfarin therapy. With a mean follow-up
f 19 months, 14% of patients experienced recurrent neu-
ologic events (one stroke, and three transient ischemic
ttacks). No patient younger than 45 years of age suffered
ecurrence, whereas 35% of patients age 45 years or more
xperienced recurrent events (p  0.02). The authors
oncluded that although PFO is easily repaired in patients
ith cryptogenic stroke, its closure does not consistently
revent ischemic event recurrence, and recurrence is more
ommon in older patients.
Devuyst et al. (60) described 30 patients with stroke and
FO who had direct surgical closure. These patients were
ounger (60 years) and met at least two of the following
our criteria: 1) recurrent clinical cerebrovascular events or
ultiple ischemic lesions on brain MRI; 2) PFO associated
ith ASA; 3) more than 50 microbubbles counted in the left
trium on contrast TEE; and 4) Valsalva maneuver or cough
receding the stroke. No patient had complications in the
erioperative period. At two years of follow-up without
ntithrombotic treatment, there was no recurrent stroke or
IA, and no new cerebral lesions developed by MRI.
ostoperative contrast TEE and TCD showed residual
hunt in two patients who had single as opposed to double
ontinuous suture closure techniques.
ONCLUSIONS
he PFO is an important risk factor for TIA and stroke,
0% of which are “cryptogenic.” The type and duration of
edical therapy needs further evaluation, especially in high
ecurrence subsets. Percutaneous PFO treatment appears
afe and beneficial not only for secondary prevention but
lso in high-risk patients without stroke. Multiple novel and
xciting technologies are emerging for treating PFO percu-
aneously (61) that promise rapid, safe, and effective PFO
reatment. Optimal technology development will require
nderstanding the PFO at histologic, cellular, and tissue
evels. Animal models under development may also aid in
his process. As new devices reach clinical application,
andomized trials comparing the treatment options will aid
n establishing cause and effect relationships between PFO
nd the myriad clinical conditions, including stroke, TIA,
nd headache.
eprint requests and correspondence: Dr. Robert S. Schwartz,
innesota Cardiovascular Research Institute, Minneapolis Heart
nstitute and Minneapolis Heart Institute Foundation, 920 East
8th Street, Suite 620, Minneapolis, Minnesota. E-mail:
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